ストックスクリーナーアプリを入手
6.50
1.96%
-0.13
アフターアワーズ：
6.50
前日終値:
$6.63
開ける：
$6.63
24時間の取引高:
239.05K
Relative Volume:
0.96
時価総額：
$324.76M
収益：
$13.56M
当期純損益:
$-26.97M
株価収益率:
-11.32
EPS:
-0.5742
ネットキャッシュフロー:
$-24.04M
1週間 パフォーマンス:
-10.22%
1か月 パフォーマンス:
+0.70%
6か月 パフォーマンス:
-46.50%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$6.335
$6.77
1週間の範囲:
$6.335
$7.40
52週間の値動き範囲:
$3.4341
$15.37
Capsovision Inc Stock (CV) Company Profile
Compare CV vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
6.50 | 361.24M | 13.56M | -26.97M | -24.04M | -0.5742 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-28 | 開始されました | Roth Capital | Buy |
| 2025-07-28 | 開始されました | The Benchmark Company | Speculative Buy |
Capsovision Inc (CV) 最新ニュース
CV | CapsoVision, Inc. Common Stock Insider Trading - Quiver Quantitative
CapsoVision shareholders re-elect directors and approve auditor at annual meeting - Investing.com
CapsoVision Stockholders Reelect Directors, Ratify 2026 Auditor - TipRanks
CapsoVision Inc. (CV) Declines 2.5% as Bearish Pressure Builds Near Key SupportCumulative Volume - newsline.com
CapsoVision Inc. (CV) Q1 2026 Earnings: EPS Miss Exceeds Estimates, Stock DeclinesPost-Earnings Reaction - newsline.com
CapsoVision Inc. (CV) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesRevenue Miss Report - newsline.com
CapsoVision Inc. (CV) Faces Selling Pressure as Shares Slide Over 4.6%Triangle Correction - newsline.com
CV Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseTax Rate Impact - newsline.com
CapsoVision Inc. (CV) Q1 2026 Earnings: EPS Miss Widens Losses, Stock DeclinesRevenue Inflection Point - newsline.com
CapsoVision (CV) awards 158,078 options to Head of Global Sales - Stock Titan
CV News | CAPSOVISION INC (NASDAQ:CV) - ChartMill
CV Q1 2026 Earnings: EPS Misses Estimates as Losses WidenBasic EPS Analysis - newsline.com
CV Q1 2026 Earnings: EPS Misses Estimates but Stock Gains 1.95%EPS Consistency Score - newsline.com
CapsoVision Inc. (CV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CapsoVision Inc. (CV) Edges Higher Amid Consolidation – Key Levels to WatchReversal Setup Alerts - The Legal Advocate
CV Q1 2026 Earnings: EPS Misses Estimates Amidst Market HeadwindsEarnings Momentum Score - newsline.com
CapsoVision (CV) Edges Higher, Consolidating Between Key LevelsFactor Timing - newsline.com
CV Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesNet Profit Margin - The Legal Advocate
CapsoVision Stock Edges Higher as FDA AI Decision Becomes the Real Test - Bez Kabli
CV Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesGuidance vs Actual - thelegaladvocate.com
CV Q1 2026 Earnings: EPS Misses Estimates Amidst Challenging QuarterDownward Estimate Revision - newsline.com
CV Q1 2026 Earnings: EPS Misses Estimates by 12%, Stock Declines Nearly 2%Pre-Earnings Setup - newsline.com
CapsoVision (CV) Q1 2026 Earnings: EPS Miss Raises Concerns Amid Operational UncertaintyProfitability Analysis - Newser
CapsoVision Inc. (CV) Gains 1.77% as Shares Test Key Resistance Near $7.23Community Pattern Alerts - Newser
CapsoVision Inc. (CV) Advances 1.18% as Price Moves Toward ResistanceMedian Line - The Legal Advocate
CapsoVision (CV) Q1 2026 Miss: What Went WrongConsensus Beat Rate - Newser
CapsoVision expects AI-assisted reading clearance around midyear, with CapsoCam Colon Gen 2 imaging and AI module targeted for Q3 2026 - MSN
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
U.S. Smart Pills Market to Reach USD 619.10 Million by 2033 as - openPR.com
CapsoVision, Inc. (CV) AI-Powered Stock Analysis - Meyka
CapsoVision Reports Stable Q1 Revenue and Expands AI Medical Pipeline - HarianBasis.co
Benchmark reiterates Speculative Buy on CapsoVision stock at $10 - Investing.com UK
Benchmark reiterates Speculative Buy on CapsoVision stock at $10 By Investing.com - Investing.com South Africa
CapsoVision Q1 Earnings Call Highlights - sharewise.com
CapsoVision Inc (NASDAQ:CV) Q1 2026 Miss Sends Stock Down 8% in After-Hours Trading - ChartMill
CAPSOVISION ($CV) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings call transcript: CapsoVision misses Q1 2026 EPS forecast, stock rises - Investing.com
Transcript: CapsoVision Q1 2026 Earnings Conference Call - Benzinga
CapsoVision Q1 2026 Earnings Call Transcript - MarketBeat
CapsoVision Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CapsoVision, Inc 1Q 2026: Revenue $2.79M, EPS $(0.15) — 10-Q Summary - TradingView
CapsoVision, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CapsoVision Reports First Quarter 2026 Financial Results - Yahoo Finance UK
CapsoVision, Inc.Common Stock (Nasdaq:CV) Stock Quote - FinancialContent
User | times-online.comCapsoVision, Inc.Common Stock (Nasdaq:CV) Stock Quote - FinancialContent
CapsoVision (CV) Climbs +1.14% — Resistance at $7.43 in Focus 2026-05-14Order Block - newsline.com
CapsoVision Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Capsovision Inc (CV) 財務データ
収益
当期純利益
現金流量
EPS
Capsovision Inc (CV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Atkinson Douglas Patrick | Head of Global Sales |
May 05 '26 |
Option Exercise |
0.57 |
34,786 |
19,692 |
107,357 |
| Harari Michele | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
59,043 |
| GOUW JULIA S | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| Imperial Joanne Carol | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| King Wen-Herng Henry | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
23,597 |
| Kuo Hui Ying | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
13,241 |
| Tsai Chen Lung | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| Petersen Rebecca Ann | Director of Clinical Affairs |
Aug 18 '25 |
Option Exercise |
0.37 |
24,834 |
9,097 |
24,834 |
2.43%
大文字化:
|
ボリューム (24 時間):